Eyepoint Pfcf Ratio vs Days Payables Outstanding Analysis

EYPT Stock

USD 8.25 0.21 2.48%

Eyepoint Pharmaceuticals financial indicator trend analysis is much more than just examining Eyepoint Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eyepoint Pharmaceuticals is a good investment. Please check the relationship between Eyepoint Pharmaceuticals Pfcf Ratio and its Days Payables Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

Pfcf Ratio vs Days Payables Outstanding

Pfcf Ratio vs Days Payables Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eyepoint Pharmaceuticals Pfcf Ratio account and Days Payables Outstanding. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Eyepoint Pharmaceuticals' Pfcf Ratio and Days Payables Outstanding is -0.03. Overlapping area represents the amount of variation of Pfcf Ratio that can explain the historical movement of Days Payables Outstanding in the same time period over historical financial statements of Eyepoint Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eyepoint Pharmaceuticals' Pfcf Ratio and Days Payables Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pfcf Ratio of Eyepoint Pharmaceuticals are associated (or correlated) with its Days Payables Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Days Payables Outstanding has no effect on the direction of Pfcf Ratio i.e., Eyepoint Pharmaceuticals' Pfcf Ratio and Days Payables Outstanding go up and down completely randomly.

Correlation Coefficient

-0.03

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Pfcf Ratio

Days Payables Outstanding

Most indicators from Eyepoint Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eyepoint Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.At this time, Eyepoint Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 87.2 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 137.3 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	2.8M	2.4M	464K	440.8K
Interest Income	292K	2.1M	6.9M	3.8M

Reconciled Depreciation Interest Income

Eyepoint Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Common Stock Shares Outstanding	Accounts Payable	Other Assets
Total Assets		-0.03	0.86	0.95	0.98	0.91	-0.95	-0.88	0.99	0.2	0.3	0.99	0.32	-0.23	0.43	0.77	0.69	0.96	0.85	0.91	1.0	0.51	0.0	0.95	0.62	0.29
Short Long Term Debt Total	-0.03		0.04	-0.11	-0.19	-0.04	0.33	-0.34	-0.16	0.56	0.63	-0.15	0.85	-0.38	0.8	0.41	0.46	0.16	0.4	-0.11	-0.08	0.5	0.86	0.14	0.53	0.24
Other Current Liab	0.86	0.04		0.89	0.8	0.77	-0.77	-0.83	0.83	0.25	0.48	0.84	0.34	-0.26	0.49	0.58	0.73	0.86	0.84	0.76	0.85	0.58	0.16	0.86	0.71	0.24
Total Current Liabilities	0.95	-0.11	0.89		0.92	0.96	-0.92	-0.87	0.95	0.15	0.26	0.96	0.16	-0.22	0.36	0.71	0.68	0.94	0.84	0.96	0.95	0.51	-0.11	0.92	0.6	0.05
Total Stockholder Equity	0.98	-0.19	0.8	0.92		0.88	-0.98	-0.79	0.99	0.05	0.2	0.99	0.19	-0.18	0.24	0.67	0.59	0.91	0.72	0.89	0.99	0.35	-0.13	0.9	0.47	0.3
Property Plant And Equipment Net	0.91	-0.04	0.77	0.96	0.88		-0.86	-0.86	0.91	0.08	0.29	0.91	0.2	-0.16	0.36	0.77	0.73	0.92	0.81	1.0	0.92	0.44	-0.13	0.92	0.59	-0.04
Net Debt	-0.95	0.33	-0.77	-0.92	-0.98	-0.86		0.73	-0.98	0.01	-0.07	-0.98	-0.03	0.15	-0.14	-0.6	-0.48	-0.86	-0.66	-0.88	-0.96	-0.28	0.27	-0.84	-0.39	-0.25
Retained Earnings	-0.88	-0.34	-0.83	-0.87	-0.79	-0.86	0.73		-0.83	-0.31	-0.53	-0.84	-0.5	0.52	-0.65	-0.83	-0.81	-0.97	-0.92	-0.83	-0.86	-0.62	-0.29	-0.92	-0.74	-0.26
Cash	0.99	-0.16	0.83	0.95	0.99	0.91	-0.98	-0.83		0.11	0.19	1.0	0.19	-0.19	0.31	0.72	0.6	0.93	0.78	0.92	0.99	0.41	-0.13	0.91	0.54	0.27
Non Current Assets Total	0.2	0.56	0.25	0.15	0.05	0.08	0.01	-0.31	0.11		0.05	0.07	0.5	-0.21	0.77	0.42	0.16	0.23	0.55	0.06	0.11	0.89	0.46	0.14	0.7	0.08
Non Currrent Assets Other	0.3	0.63	0.48	0.26	0.2	0.29	-0.07	-0.53	0.19	0.05		0.25	0.76	-0.25	0.55	0.36	0.84	0.43	0.48	0.22	0.3	0.31	0.69	0.54	0.44	0.26
Cash And Short Term Investments	0.99	-0.15	0.84	0.96	0.99	0.91	-0.98	-0.84	1.0	0.07	0.25		0.21	-0.2	0.3	0.71	0.64	0.94	0.77	0.92	1.0	0.4	-0.1	0.93	0.52	0.27
Net Receivables	0.32	0.85	0.34	0.16	0.19	0.2	-0.03	-0.5	0.19	0.5	0.76	0.21		-0.17	0.84	0.6	0.68	0.4	0.59	0.12	0.28	0.55	0.84	0.47	0.62	0.47
Common Stock Total Equity	-0.23	-0.38	-0.26	-0.22	-0.18	-0.16	0.15	0.52	-0.19	-0.21	-0.25	-0.2	-0.17		-0.26	-0.15	-0.23	-0.43	-0.29	-0.16	-0.21	-0.26	-0.33	-0.23	-0.24	-0.34
Non Current Liabilities Total	0.43	0.8	0.49	0.36	0.24	0.36	-0.14	-0.65	0.31	0.77	0.55	0.3	0.84	-0.26		0.74	0.62	0.53	0.81	0.29	0.36	0.83	0.71	0.51	0.84	0.27
Inventory	0.77	0.41	0.58	0.71	0.67	0.77	-0.6	-0.83	0.72	0.42	0.36	0.71	0.6	-0.15	0.74		0.67	0.81	0.88	0.74	0.74	0.61	0.27	0.81	0.7	0.2
Other Current Assets	0.69	0.46	0.73	0.68	0.59	0.73	-0.48	-0.81	0.6	0.16	0.84	0.64	0.68	-0.23	0.62	0.67		0.77	0.78	0.67	0.68	0.53	0.45	0.86	0.66	0.12
Other Stockholder Equity	0.96	0.16	0.86	0.94	0.91	0.92	-0.86	-0.97	0.93	0.23	0.43	0.94	0.4	-0.43	0.53	0.81	0.77		0.9	0.9	0.95	0.55	0.14	0.96	0.68	0.27
Total Liab	0.85	0.4	0.84	0.84	0.72	0.81	-0.66	-0.92	0.78	0.55	0.48	0.77	0.59	-0.29	0.81	0.88	0.78	0.9		0.78	0.81	0.81	0.34	0.88	0.87	0.19
Property Plant And Equipment Gross	0.91	-0.11	0.76	0.96	0.89	1.0	-0.88	-0.83	0.92	0.06	0.22	0.92	0.12	-0.16	0.29	0.74	0.67	0.9	0.78		0.92	0.41	-0.21	0.9	0.56	-0.05
Total Current Assets	1.0	-0.08	0.85	0.95	0.99	0.92	-0.96	-0.86	0.99	0.11	0.3	1.0	0.28	-0.21	0.36	0.74	0.68	0.95	0.81	0.92		0.43	-0.04	0.95	0.56	0.28
Intangible Assets	0.51	0.5	0.58	0.51	0.35	0.44	-0.28	-0.62	0.41	0.89	0.31	0.4	0.55	-0.26	0.83	0.61	0.53	0.55	0.81	0.41	0.43		0.44	0.51	0.82	-0.01
Common Stock	0.0	0.86	0.16	-0.11	-0.13	-0.13	0.27	-0.29	-0.13	0.46	0.69	-0.1	0.84	-0.33	0.71	0.27	0.45	0.14	0.34	-0.21	-0.04	0.44		0.17	0.4	0.39
Common Stock Shares Outstanding	0.95	0.14	0.86	0.92	0.9	0.92	-0.84	-0.92	0.91	0.14	0.54	0.93	0.47	-0.23	0.51	0.81	0.86	0.96	0.88	0.9	0.95	0.51	0.17		0.63	0.23
Accounts Payable	0.62	0.53	0.71	0.6	0.47	0.59	-0.39	-0.74	0.54	0.7	0.44	0.52	0.62	-0.24	0.84	0.7	0.66	0.68	0.87	0.56	0.56	0.82	0.4	0.63		0.18
Other Assets	0.29	0.24	0.24	0.05	0.3	-0.04	-0.25	-0.26	0.27	0.08	0.26	0.27	0.47	-0.34	0.27	0.2	0.12	0.27	0.19	-0.05	0.28	-0.01	0.39	0.23	0.18

Click cells to compare fundamentals

Eyepoint Pharmaceuticals Account Relationship Matchups

Eyepoint Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	73.3M	91.7M	263.4M	180.4M	355.2M	372.9M
Short Long Term Debt Total	50.6M	46.4M	38.4M	45.8M	4.9M	4.7M
Other Current Liab	6.8M	687K	14.4M	16.4M	18.2M	19.1M
Total Current Liabilities	11.9M	14.9M	23.7M	34.5M	63.3M	66.4M
Total Stockholder Equity	8.3M	18.5M	184.4M	96.4M	266.3M	279.6M
Property Plant And Equipment Net	3.1M	3.2M	2.3M	6.0M	10.2M	10.7M
Net Debt	28.4M	(4.6M)	(140.2M)	(49.9M)	(276.4M)	(262.5M)
Retained Earnings	(465.3M)	(510.7M)	(569.1M)	(671.4M)	(742.1M)	(705.0M)
Cash	22.2M	44.9M	178.6M	95.6M	281.3M	295.3M
Non Current Assets Total	31.3M	28.6M	25.6M	7.5M	10.4M	9.9M
Non Currrent Assets Other	260K	150K	507K	626K	1.4M	281.2K
Cash And Short Term Investments	22.2M	44.9M	211.6M	144.6M	331.1M	347.6M
Net Receivables	11.7M	9.5M	18.4M	15.5M	805K	764.8K
Common Stock Total Equity	39K	74K	109K	18K	30.6K	29.1K
Liabilities And Stockholders Equity	73.3M	91.7M	263.4M	180.4M	355.2M	372.9M
Non Current Liabilities Total	53.1M	58.3M	55.3M	49.5M	25.6M	17.4M
Inventory	2.1M	5.3M	3.6M	2.9M	3.9M	4.1M
Other Current Assets	8.1M	3.4M	7.9M	18.9M	9.0M	9.5M
Other Stockholder Equity	472.7M	528.4M	752.6M	766.9M	1.0B	1.1B
Total Liab	65.0M	73.2M	79.0M	84.0M	88.9M	93.3M
Property Plant And Equipment Gross	3.4M	3.2M	2.3M	6.0M	12.8M	13.4M
Total Current Assets	42.1M	63.1M	237.7M	172.8M	344.8M	362.0M
Intangible Assets	31.4M	27.7M	25.2M	22.7M	20.5M	19.1M
Common Stock	472.8M	528.4M	752.6M	766.9M	49K	46.6K
Common Stock Shares Outstanding	10.4M	12.8M	28.8M	37.3M	38.9M	40.8M
Accounts Payable	11.4M	4.8M	7.4M	5.9M	6.5M	6.8M
Accumulated Other Comprehensive Income	838K	840K	841K	786K	864K	1.2M
Property Plant Equipment	357K	630K	2.3M	1.4M	1.2M	1.3M
Current Deferred Revenue	15K	945K	1.1M	1.2M	38.6M	36.7M
Long Term Debt	47.2M	38.0M	36.6M	29.3M	33.7M	35.4M
Short Term Debt	481K	8.4M	782K	11.1M	563K	534.9K
Other Liab	3M	18.0M	16.9M	14.2M	16.3M	8.6M
Net Tangible Assets	(19.3M)	(6.7M)	161.6M	96.4M	110.8M	116.4M
Capital Surpluse	472.7M	528.4M	752.6M	766.9M	881.9M	467.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC